WO1999022731A1 - Method and composition for treatment of sexual dysfunction - Google Patents
Method and composition for treatment of sexual dysfunction Download PDFInfo
- Publication number
- WO1999022731A1 WO1999022731A1 PCT/AU1998/000906 AU9800906W WO9922731A1 WO 1999022731 A1 WO1999022731 A1 WO 1999022731A1 AU 9800906 W AU9800906 W AU 9800906W WO 9922731 A1 WO9922731 A1 WO 9922731A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- milrinone
- alpha
- injection
- atropine
- erection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU10116/99A AU1011699A (en) | 1997-10-30 | 1998-10-30 | Method and composition for treatment of sexual dysfunction |
EP98952416A EP1028726A1 (en) | 1997-10-30 | 1998-10-30 | Method and composition for treatment of sexual dysfunction |
CA002315221A CA2315221A1 (en) | 1997-10-30 | 1998-10-30 | Method and composition for treatment of sexual dysfunction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP0103 | 1997-10-30 | ||
AUPP0103A AUPP010397A0 (en) | 1997-10-30 | 1997-10-30 | Method and composition for treatment of sexual dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999022731A1 true WO1999022731A1 (en) | 1999-05-14 |
Family
ID=3804383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1998/000906 WO1999022731A1 (en) | 1997-10-30 | 1998-10-30 | Method and composition for treatment of sexual dysfunction |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1028726A1 (en) |
KR (1) | KR19990037550A (en) |
AU (1) | AUPP010397A0 (en) |
CA (1) | CA2315221A1 (en) |
WO (1) | WO1999022731A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1097707A1 (en) * | 1999-11-08 | 2001-05-09 | Pfizer Limited | Treatment of female sexual dysfunction |
WO2001041807A2 (en) * | 1999-12-10 | 2001-06-14 | Vivus, Inc. | Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US7176238B1 (en) | 1999-03-01 | 2007-02-13 | Nitromed Inc. | Nitrostated and nitrosylated prostaglandins, compositions and methods of use |
CN100337629C (en) * | 2004-04-07 | 2007-09-19 | 鲁南制药集团股份有限公司 | Milrinone sodium chloride injection and production thereof |
USRE43372E1 (en) | 1999-03-05 | 2012-05-08 | Duke University | C16 unsaturated FP-selective prostaglandins analogs |
US8906962B2 (en) | 2000-03-31 | 2014-12-09 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
CN104739759A (en) * | 2015-04-02 | 2015-07-01 | 海南合瑞制药股份有限公司 | Pharmaceutical composition containing milrinone compound |
US9346837B2 (en) | 2000-03-31 | 2016-05-24 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995005172A1 (en) * | 1993-08-13 | 1995-02-23 | Zonagen, Inc. | Methods for modulating the human sexual response |
DE4338948A1 (en) * | 1993-11-15 | 1995-05-18 | Carlen Judith | Treating erectile dysfunction without causing side-effects |
US5583144A (en) * | 1995-02-24 | 1996-12-10 | Kral; John G. | Methods for treating erectile impotence |
-
1997
- 1997-10-30 AU AUPP0103A patent/AUPP010397A0/en not_active Abandoned
-
1998
- 1998-10-30 WO PCT/AU1998/000906 patent/WO1999022731A1/en not_active Application Discontinuation
- 1998-10-30 EP EP98952416A patent/EP1028726A1/en not_active Withdrawn
- 1998-10-30 KR KR1019980046467A patent/KR19990037550A/en not_active Application Discontinuation
- 1998-10-30 CA CA002315221A patent/CA2315221A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995005172A1 (en) * | 1993-08-13 | 1995-02-23 | Zonagen, Inc. | Methods for modulating the human sexual response |
DE4338948A1 (en) * | 1993-11-15 | 1995-05-18 | Carlen Judith | Treating erectile dysfunction without causing side-effects |
US5583144A (en) * | 1995-02-24 | 1996-12-10 | Kral; John G. | Methods for treating erectile impotence |
Non-Patent Citations (5)
Title |
---|
ANALES D'UROLOGIE, Vol. 25, No. 2, (1991), STIEF C.G., "Pathophysiology of Erectile Dysfunction Due to Cavernous Venous Insufficiency", pages 64-66. * |
INT. J. IMPOTENCE RES., Vol. 8, No. 3, September 1996, STIEF et al., "The Effect of the Specific Phosphodiesterase (PDE) - Inhibitors on Human Rabbit Cavernous Tissue In Vitro and In Vivo", page 127, Abstract D20. * |
J. UROLOGY, Vol. 159, No. 4, April 1998, STIEF et al., "The Effect of the Specific Phosphodiesterase (PDE) Inhibitors on Human and Rabbit Cavernous Tissue In Vitro and In Vivo", pages 1390-1393. * |
SPANWASSER et al., "The Effects of Inhibitors of Phosphodiesterase (PDE) on Smooth Muscle Relaxation of Human and Rabbit Isolated Cavernasal Tissue", Abstract D22. * |
THE MERCK INDEX, 12 Edn 1996, MERCK & CO., Mon. No. 6284, 1036, 7417, 2238, 8063, 8064, 7151, 907. * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6462044B2 (en) | 1996-11-01 | 2002-10-08 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6930113B2 (en) | 1996-11-01 | 2005-08-16 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US7176238B1 (en) | 1999-03-01 | 2007-02-13 | Nitromed Inc. | Nitrostated and nitrosylated prostaglandins, compositions and methods of use |
US7772278B2 (en) | 1999-03-01 | 2010-08-10 | Nitromed, Inc. | Nitrosated and nitrosylated prostaglandins, compositions and methods of use |
US7449595B2 (en) | 1999-03-01 | 2008-11-11 | Nitromed, Inc. | Nitrosated and nitrosylated prostaglandins, compositions and methods of use |
USRE43372E1 (en) | 1999-03-05 | 2012-05-08 | Duke University | C16 unsaturated FP-selective prostaglandins analogs |
EP1097707A1 (en) * | 1999-11-08 | 2001-05-09 | Pfizer Limited | Treatment of female sexual dysfunction |
EP1097706A1 (en) * | 1999-11-08 | 2001-05-09 | Pfizer Limited | Phosphodiesterase inhibitors for the treatment of female sexual dysfunction |
US6734186B1 (en) | 1999-11-08 | 2004-05-11 | Pfizer Inc. | Compounds for the treatment of female sexual dysfunction |
WO2001041807A3 (en) * | 1999-12-10 | 2002-02-14 | Vivus Inc | Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
WO2001041807A2 (en) * | 1999-12-10 | 2001-06-14 | Vivus, Inc. | Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US8906962B2 (en) | 2000-03-31 | 2014-12-09 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US9346837B2 (en) | 2000-03-31 | 2016-05-24 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US9579270B2 (en) | 2000-03-31 | 2017-02-28 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US9675539B2 (en) | 2000-03-31 | 2017-06-13 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
CN100337629C (en) * | 2004-04-07 | 2007-09-19 | 鲁南制药集团股份有限公司 | Milrinone sodium chloride injection and production thereof |
CN104739759A (en) * | 2015-04-02 | 2015-07-01 | 海南合瑞制药股份有限公司 | Pharmaceutical composition containing milrinone compound |
Also Published As
Publication number | Publication date |
---|---|
AUPP010397A0 (en) | 1997-11-20 |
EP1028726A1 (en) | 2000-08-23 |
KR19990037550A (en) | 1999-05-25 |
CA2315221A1 (en) | 1999-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nehra et al. | Rationale for combination therapy of intraurethral prostaglandin E1 and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy | |
CA2636638C (en) | A method of treating an acute vascular disorder | |
Alm et al. | The effects of pilocarpine and neostigmine on the blood flow through the anterior uvea in monkeys. A study with radioactively labelled microspheres | |
WO1999022731A1 (en) | Method and composition for treatment of sexual dysfunction | |
US6338862B1 (en) | Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors | |
KR20010033092A (en) | Combination effective for the treatment of impotence | |
Chao et al. | Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction | |
Ayd Jr | A preliminary report on Marsilid | |
Costa et al. | Efficiency and side effects of intracavernous injections of moxisylyte in impotent patients: a dose-finding study versus placebo | |
Zentgraf et al. | Diagnosis and therapy of erectile dysfunction using papaverine and phentolamine | |
Nicholson et al. | Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer | |
Marshall et al. | Improved hemodynamic response after long-term intracavernous injection for impotence | |
Lee et al. | Dexfenfluramine as a mitogen signals through the formation of superoxide anion | |
EP0618798B1 (en) | Pyridylguanidine compounds for treatment of erectile dysfunction | |
Andersson et al. | Oral α adrenoceptor blockade as a treatment of erectile dysfunction | |
AU1011699A (en) | Method and composition for treatment of sexual dysfunction | |
EP0305181A2 (en) | Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin | |
US5541211A (en) | Administration of atipamezole to elicit a yohimbine-like alpha-adrenoreceptor antagonistic noradrenergic transmission | |
US4687771A (en) | Method for treatment of male impotence | |
Nakada et al. | Primary aldosteronism treated by trilostane (3, β-hydroxysteroid dehydrogenase inhibitor) | |
Shmueli et al. | Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents | |
Awadzi et al. | The chemotherapy of onchocerciasis IX: The effect of prednisone plus cyproheptadine on the Mazzotti reaction | |
Tarhan et al. | Effect of intracavernosal sodium nitroprusside in impotence | |
KR19990069591A (en) | Sexual Dysfunction Therapeutics and Treatment Methods | |
Riley | Alpha adrenoceptors and human sexual function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10116/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 504802 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998952416 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2315221 Country of ref document: CA Kind code of ref document: A Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1998952416 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09555458 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 10116/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998952416 Country of ref document: EP |